Table 1.
Clinical responses to two 105 pfu doses of rcp45 vaccine, biologically-derived cp45 vaccine,* or placebo in young children
| % with indicated illness |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subjects’ HPIV3 status |
Vaccine | Dose | No. of subjects |
Fever | URI | LRI | Cough | Otitis Media |
Any respiratory or febrile illness |
| Seropositive | rcp45 | 1 | 5 | 40 | 40 | 0 | 0 | 0 | 60 |
| Seropositive | rcp45 | 2 | 5 | 0 | 20 | 0 | 0 | 0 | 20 |
| Seronegative | rcp45 | 1 | 24 | 13 | 33 | 0 | 4 | 0 | 37 |
| Seronegative | rcp45 | 2 | 24 | 4 | 25 | 0 | 0 | 4 | 25 |
| Seronegative | placebo | 1 | 15 | 13 | 53 | 0 | 7 | 13 | 53 |
| Seronegative | placebo | 2 | 15 | 13 | 47 | 0 | 7 | 0 | 53 |
| Seronegative* | cp45 | 1 | 21 | 24 | 52 | 10 | 19 | 19 | 62 |
| Seronegative* | placebo | 1 | 4 | 25 | 50 | 0 | 25 | 0 | 50 |
URI= upper respiratory illness; LRI= lower respiratory illness. Data from a single seronegative child who withdrew following receipt of rcp45 (and was asymptomatic) are not included.
*
Data from recipients of the biologically-derived cp45 vaccine are from a previous study (Karron RA et al. Pediatr Infect Dis J, 2003; 22:394-405.)